An experimental study of ovarian cancer imaging and therapy by paclitaxel-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound

Gao, Yanling; Chen, Shaoyun; Li, Wenjuan; Wang, Huilin; Xiao, Kelin; Wu, Lijuan; Li, Yao; Li, Huiqin; Li, Hongping; Zhu, Yue

doi:10.1016/j.bbrc.2018.08.156

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a new emerging imaging technique, ultrasound molecular imaging combines the unique intrinsic advantages of ultrasound imaging with the capability of molecular imaging. , The principle is based on the specific molecular markers that can be attached to the surface of nanosized contrast agents of ultrasound, so these nano-contrast agents are capable of targeting the specific antigen or antibody of the disease-related cells or tissues. − After the nano-contrast agents accumulate to the specific location by intravenous injection, low-intensity focused ultrasound (LIFU) is used to induce the nano-contrast agents undergoing liquid–gas phase change and converting into microbubbles, which can be easily detected by diagnostic ultrasound. − This diagnostic-imaging approach provides a novel noninvasive, economical, real-time imaging technique for inspecting the specific molecules in the disease tissue. − Recently, several molecular probes have been designed for ultrasound molecular imaging in animal models with liver tumors, retinoblastoma and liver fibrosis, but the rational design of phase-changeable nano-contrast agents on the ultrasound molecular imaging of myocardial fibrosis is still highly challenging. − …”

Section: Introductionmentioning

confidence: 99%

Construction of CNA35 Collagen-Targeted Phase-Changeable Nanoagents for Low-Intensity Focused Ultrasound-Triggered Ultrasound Molecular Imaging of Myocardial Fibrosis in Rabbits

Zhou

Zeng

Xiong

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

show abstract

Section: Introductionmentioning

confidence: 99%

Construction of CNA35 Collagen-Targeted Phase-Changeable Nanoagents for Low-Intensity Focused Ultrasound-Triggered Ultrasound Molecular Imaging of Myocardial Fibrosis in Rabbits

Zhou

Zeng

Xiong

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…The mechanism of FRBI as an antagonist of lhcgr also has potential in aiding ovarian diseases and ovarian and follicular functioning in order to promote fertility in humans and animals (Wei et al, 2017;Lai et al, 2018). Although lhcgr has been identified as a potential drug target for cancer therapy and methods to apply this have been refined, there have so far been very few studies showing how these anti-cancer drugs affect the expression of lhcgr (Cavalli et al, 2016;Gao et al, 2018). Further studies of lhcgr expression levels in relation to drug application are needed to reveal if it can be used as an early expressed gene for unravelling confounding sex variables during anti-cancer drug development.…”

Section: Lhcgrmentioning

confidence: 99%

Sex blind: bridging the gap between drug exposure and sex-related gene expression in Danio rerio using next-generation sequencing (NGS) data and a literature review to find the missing links in pharmaceutical and environmental toxicology studies

King¹,

Zenker²

2023

Front. Toxicol.

View full text Add to dashboard Cite

The sex of both humans and Danio rerio has previously been shown to affect the way individuals respond to drug exposure. Genes which allow identification of sex in juvenile zebrafish show potential to reveal these confounding variables between sex in toxicological and preclinical trials but the link between these is so far missing. These sex-specific, early expressed genes where expression is not altered by drug exposure must be carefully selected for this purpose. We aimed to discover genes which can be used in pharmaceutical trials and environmental toxicology studies to uncover sex-related variations in gene expression with drug application using the model organism Danio rerio. Previously published early sex determining genes from King et al. were evaluated as well as additional genes selected from our zebrafish Next-generation sequencing (NGS) data which are known from previously published works not to be susceptible to changes in expression with drug exposure. NGS revealed a further ten female-specific genes (vtg1, cyp17a1, cyp19a1a, igf3, ftz-f1, gdf9, foxl2a, Nr0b1, ipo4, lhcgr) and five male related candidate genes (FKBP5, apobb1, hbaa1, dmrt1, spata6) which are also expressed in juvenile zebrafish, 28 days post fertilisation (dpf). Following this, a literature review was performed to classify which of these early-expressed sex specific genes are already known to be affected by drug exposure in order to determine candidate genes to be used in pharmaceutical trials or environmental toxicology testing studies. Discovery of these early sex-determining genes in Danio rerio will allow identification of sex-related responses to drug testing to improve sex-specific healthcare and the medical treatment of human patients.

show abstract

“…In another strategy, anti-LHRH receptor antibody and PTX were loaded to phase-transformation lipid nanoparticles (PTNP) to fabricate PTX-anti-LHRHR-PTNPs. When combined with low-intensity focused ultrasound (LIFU), PTX-anti-LHRHR-PTNPs led to an increase in the circulatory half-life of PTX and increased its penetration to the tumor site resulting in an efficient reduction in the size of xenograft of OVCAR-3 tumor in nude mice ( 54 ).…”

Section: Us-mediated Drug Delivery Using Tumor Markersmentioning

confidence: 99%

Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies

et al. 2022

View full text Add to dashboard Cite

Ovarian cancer (OC) has the greatest mortality rate among gynecological cancers, with a five-year survival rate of <50%. Contemporary adjuvant chemotherapy mostly fails in the case of OCs that are refractory, metastatic, recurrent, and drug-resistant. Emerging ultrasound (US)-mediated technologies show remarkable promise in overcoming these challenges. Absorption of US waves by the tissue results in the generation of heat due to its thermal effect causing increased diffusion of drugs from the carriers and triggering sonoporation by increasing the permeability of the cancer cells. Certain frequencies of US waves could also produce a cavitation effect on drug-filled microbubbles (MBs, phospholipid bilayers) thereby generating shear force and acoustic streaming that could assist drug release from the MBs, and promote the permeability of the cell membrane. A new class of nanoparticles that carry therapeutic agents and are guided by US contrast agents for precision delivery to the site of the ovarian tumor has been developed. Phase-shifting of nanoparticles by US sonication has also been engineered to enhance the drug delivery to the ovarian tumor site. These technologies have been used for targeting the ovarian cancer stem cells and protein moieties that are particularly elevated in OCs including luteinizing hormone-releasing hormone, folic acid receptor, and vascular endothelial growth factor. When compared to healthy ovarian tissue, the homeostatic parameters at the tissue microenvironment including pH, oxygen levels, and glucose metabolism differ significantly in ovarian tumors. US-based technologies have been developed to take advantage of these tumor-specific alterations for precision drug delivery. Preclinical efficacy of US-based targeting of currently used clinical chemotherapies presented in this review has the potential for rapid human translation, especially for formulations that use all substances that are deemed to be generally safe by the U.S. Food and Drug Administration.

show abstract

An experimental study of ovarian cancer imaging and therapy by paclitaxel-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound

Cited by 5 publications

References 21 publications

Construction of CNA35 Collagen-Targeted Phase-Changeable Nanoagents for Low-Intensity Focused Ultrasound-Triggered Ultrasound Molecular Imaging of Myocardial Fibrosis in Rabbits

Construction of CNA35 Collagen-Targeted Phase-Changeable Nanoagents for Low-Intensity Focused Ultrasound-Triggered Ultrasound Molecular Imaging of Myocardial Fibrosis in Rabbits

Sex blind: bridging the gap between drug exposure and sex-related gene expression in Danio rerio using next-generation sequencing (NGS) data and a literature review to find the missing links in pharmaceutical and environmental toxicology studies

Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies

Contact Info

Product

Resources

About